The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

D Baker, G Pryce, LK James, M Marta… - Multiple sclerosis and …, 2020 - Elsevier
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
被引用次数：92 相关文章

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

D Baker, G Pryce, LK James, M Marta… - Multiple Sclerosis and …, 2020 - europepmc.org
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

D Baker, G Pryce, LK James… - Multiple sclerosis …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

D Baker, G Pryce, LK James, M Marta… - Multiple Sclerosis and …, 2020 - msard-journal.com
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis

D Baker, G Pryce, LK James, M Marta, K Schmierer - medRxiv, 2020 - medrxiv.org
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

D Baker, G Pryce, LK James, M Marta… - Mult Scler Relat …, 2020 - qmro.qmul.ac.uk
OBJECTIVE: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis

D Baker, G Pryce, LK James, M Marta, K Schmierer - 2020 - europepmc.org
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

[引用][C] The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis

D Baker, G Pryce, LK James, M Marta, K Schmierer - medRxiv, 2020 - qmro.qmul.ac.uk
The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance
in multiple sclerosis Toggle navigation Login Toggle navigation The ocrelizumab phase II …